Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07661979 · ClinicalTrials.gov registry record · Phase 4
Opzelura Experience Study
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Not yet
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT07661979 is a Phase 4 study that has not yet begun recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 50 participants.
The verdict
NCT07661979, a Phase 4 study, has not yet begun recruiting, sponsored by Wake Forest University Health Sciences.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
Atopic dermatitis is a common multifactorial skin disease. Topicals are the mainstay of treatment, but adherence to topicals is often abysmal, possibly worsened by the complexity of recommended treatment algorithms. Giving patients a simple, one drug approach may be advantageous.
Interventions
- DRUG ruxolitinib
- DRUG ruxolitinib and an Eczema Action Plan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-08 |
| Est. Completion | 2027-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07661979
The ClinicalTrials.gov registry entry for NCT07661979 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ruxolitinib is the first listed.
NCT07661979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07661979 about?
NCT07661979 is a clinical study titled "Opzelura Experience Study". Atopic dermatitis is a common multifactorial skin disease. Topicals are the mainstay of treatment, but adherence to topicals is often abysmal, possibly worsened by the complexity of recommended treatment algorithms. Giving patients a simple, one drug approach may be advantageous.
What is the current status of trial NCT07661979?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2026-08. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07661979?
The interventions under investigation include: ruxolitinib (DRUG), ruxolitinib and an Eczema Action Plan (DRUG).
Who is sponsoring clinical trial NCT07661979?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.